To assess the efficacy and safety of PF-3512676 administered in combination with erlotinib in patients with advanced EGFR-positive non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
43
PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity. Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
Progression-Free Survival
Time frame: 50Events
Overall Safety Profile
Time frame: 28 days post treatment
Time to Tumor Progression
Time frame: End of treatment
Overall Objective Response Rate
Time frame: Time of disease progression
Duration of Response
Time frame: Time of disease progression
Overall Survival
Time frame: Time of death
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Pfizer Investigational Site
Daphne, Alabama, United States
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Corona, California, United States
Pfizer Investigational Site
Glendora, California, United States
Pfizer Investigational Site
Greenbrae, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
Pomona, California, United States
Pfizer Investigational Site
Rancho Cucamonga, California, United States
Pfizer Investigational Site
San Mateo, California, United States
...and 25 more locations